RS20070318A - Sterile formulations of modifier of immune response and processes - Google Patents
Sterile formulations of modifier of immune response and processesInfo
- Publication number
- RS20070318A RS20070318A RSP-2007/0318A RSP20070318A RS20070318A RS 20070318 A RS20070318 A RS 20070318A RS P20070318 A RSP20070318 A RS P20070318A RS 20070318 A RS20070318 A RS 20070318A
- Authority
- RS
- Serbia
- Prior art keywords
- imidazo
- modifier
- processes
- immune response
- sterile formulations
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 239000003607 modifier Substances 0.000 title 1
- 230000001954 sterilising effect Effects 0.000 abstract 2
- 238000004659 sterilization and disinfection Methods 0.000 abstract 2
- ZXBCLVSLRUWISJ-UHFFFAOYSA-N 2-methyl-1-(2-methylpropyl)imidazo[4,5-c][1,5]naphthyridin-4-amine Chemical compound C1=CC=NC2=C3N(CC(C)C)C(C)=NC3=C(N)N=C21 ZXBCLVSLRUWISJ-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 abstract 1
- 229950010550 resiquimod Drugs 0.000 abstract 1
- 229950008380 sotirimod Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Opisana je farmaceutska kompozicija koja sadrži aktivnu supstancu izabranu iz grupe koju čine imikuimod (l-(2-metilpropil)-1H-imidazo[4,5-c]hinolin-4-amin), sotirimod (2-metil-l-(2-metilpropil)-1H-imidazo[4,5-c][l,5]naftiridin-4-amin) i rezikuimod (4-amino-α,α-dimetil-2-etoksimetil-1H-imidazo[4,5-c]hinolin-1-etanol) koja je stabilna prema sterilizaciji i pogodna za lokalnu primenu direktno na mesta na tkivu koja su probijena i koja je bila steriliziovana, i upakovana kompozicija koja je sterilizovana i postupke sterilizacije ovih jedinjenja.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82087606P | 2006-07-31 | 2006-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
RS20070318A true RS20070318A (en) | 2009-05-06 |
Family
ID=38617896
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20120043A RS52120B (sr) | 2006-07-31 | 2007-07-19 | Sterilne formulacije modifikatora imunog odgovora i postupci |
RSP-2007/0318A RS20070318A (en) | 2006-07-31 | 2007-07-27 | Sterile formulations of modifier of immune response and processes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20120043A RS52120B (sr) | 2006-07-31 | 2007-07-19 | Sterilne formulacije modifikatora imunog odgovora i postupci |
Country Status (24)
Country | Link |
---|---|
US (1) | US8124096B2 (sr) |
EP (1) | EP1891953B1 (sr) |
AR (1) | AR062121A1 (sr) |
AT (1) | ATE532511T1 (sr) |
AU (1) | AU2007279376B2 (sr) |
CA (1) | CA2659733A1 (sr) |
CL (1) | CL2007002228A1 (sr) |
CY (1) | CY1112264T1 (sr) |
DK (1) | DK1891953T3 (sr) |
ES (1) | ES2375744T3 (sr) |
HR (1) | HRP20120128T1 (sr) |
IL (1) | IL184652A (sr) |
ME (1) | MEP20608A (sr) |
NO (1) | NO338958B1 (sr) |
PE (1) | PE20080523A1 (sr) |
PL (1) | PL1891953T3 (sr) |
PT (1) | PT1891953E (sr) |
RS (2) | RS52120B (sr) |
RU (1) | RU2474425C2 (sr) |
SI (1) | SI1891953T1 (sr) |
UA (1) | UA93496C2 (sr) |
UY (1) | UY30513A1 (sr) |
WO (1) | WO2008016475A2 (sr) |
ZA (1) | ZA200900618B (sr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
RU2006105101A (ru) * | 2003-08-27 | 2007-10-10 | 3М Инновейтив Пропертиз Компани (US) | Арилокси и арилалкиленокси замещенные имидазохинолины |
NZ546273A (en) | 2003-10-03 | 2009-05-31 | Coley Pharm Group Inc | Alkoxy substituted imidazoquinolines |
JP2007508305A (ja) | 2003-10-03 | 2007-04-05 | スリーエム イノベイティブ プロパティズ カンパニー | ピラゾロピリジンおよびその類似物 |
CA2547020C (en) | 2003-11-25 | 2014-03-25 | 3M Innovative Properties Company | 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier |
US8541438B2 (en) | 2004-06-18 | 2013-09-24 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
AU2005322898B2 (en) | 2004-12-30 | 2011-11-24 | 3M Innovative Properties Company | Chiral fused (1,2)imidazo(4,5-c) ring compounds |
JP5313502B2 (ja) | 2004-12-30 | 2013-10-09 | スリーエム イノベイティブ プロパティズ カンパニー | 置換キラル縮合[1,2]イミダゾ[4,5−c]環状化合物 |
AU2006338521A1 (en) | 2005-02-09 | 2007-10-11 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods |
US20080318998A1 (en) * | 2005-02-09 | 2008-12-25 | Coley Pharmaceutical Group, Inc. | Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines |
AU2006216997A1 (en) | 2005-02-11 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Substituted imidazoquinolines and imidazonaphthyridines |
WO2006098852A2 (en) * | 2005-02-23 | 2006-09-21 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinolines |
US8846710B2 (en) * | 2005-02-23 | 2014-09-30 | 3M Innovative Properties Company | Method of preferentially inducing the biosynthesis of interferon |
US8158794B2 (en) * | 2005-02-23 | 2012-04-17 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
WO2007030775A2 (en) | 2005-09-09 | 2007-03-15 | Coley Pharmaceutical Group, Inc. | Amide and carbamate derivatives of n-{2-[4-amino-2- (ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods |
ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
ES2429170T3 (es) | 2005-11-04 | 2013-11-13 | 3M Innovative Properties Company | 1H-Imidazoquinolinas sustituidas con hidroxilo y alcoxilo y métodos |
EP3085373A1 (en) | 2006-02-22 | 2016-10-26 | 3M Innovative Properties Company | Immune response modifier conjugates |
US8329721B2 (en) | 2006-03-15 | 2012-12-11 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods |
WO2008030511A2 (en) * | 2006-09-06 | 2008-03-13 | Coley Pharmaceuticial Group, Inc. | Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes |
GB0715428D0 (en) * | 2007-08-08 | 2007-09-19 | Imp Innovations Ltd | Compositions and uses thereof |
US20100160368A1 (en) * | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
DK2378876T3 (en) | 2008-12-19 | 2019-03-11 | Medicis Pharmaceutical Corp | IMIQUIMOD FORMULATIONS WITH LOWER DOSAGE STRENGTH AND SHORT-TERM DOSAGE PLAN FOR TREATMENT OF ACTINIC KERATOSIS |
US8920392B2 (en) | 2009-05-05 | 2014-12-30 | Watson Laboratories, Inc. | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
PL2453747T3 (pl) | 2009-07-13 | 2018-02-28 | Medicis Pharmaceutical Corporation | Preparaty imikwimodu o niższej mocy dawki i krótkie schematy dawkowania do leczenia brodawek narządów płciowych i okolic odbytu |
BR112013003772A2 (pt) | 2010-08-17 | 2016-08-02 | 3M Innovative Properties Co | composições de compostos modificadores de resposta imunológica lipidadas, formulações e métodos |
JP6415979B2 (ja) | 2011-06-03 | 2018-10-31 | スリーエム イノベイティブ プロパティズ カンパニー | ヒドラジノ1h−イミダゾキノリン−4−アミン及びこれから調製された複合体 |
BR112013031028A2 (pt) | 2011-06-03 | 2016-11-29 | 3M Innovative Properties Co | conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles |
JP6335337B2 (ja) | 2014-02-21 | 2018-05-30 | アヴァディム・テクノロジーズ,インコーポレイテッド | 尿道カテーテルの維持のための方法 |
US20160158393A1 (en) * | 2014-02-21 | 2016-06-09 | Avadim Technologies, Inc. | Method for Improving Health Outcomes |
MX2017006657A (es) | 2014-11-19 | 2018-03-15 | Avadim Tech Inc | Método para la prevención y el tratamiento del acné. |
GB201505347D0 (en) * | 2015-03-27 | 2015-05-13 | Salupont Consulting Ltd | Sterilisation of s-nitrosothiols |
JP7197244B2 (ja) | 2017-12-20 | 2022-12-27 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答調節剤として使用するための分岐鎖連結基を有するアミド置換イミダゾ[4,5-c]キノリン化合物 |
CN109481674A (zh) * | 2018-11-14 | 2019-03-19 | 大连亚维药业有限公司 | 一种生物无菌乳膏药物的生产方法 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US24906A (en) * | 1859-07-26 | Simeon goodfellow | ||
IT610737A (sr) | 1955-11-18 | 1900-01-01 | ||
US3700674A (en) | 1969-04-30 | 1972-10-24 | American Cyanamid Co | 4-alkylamino-3-nitroquinolines |
US4013665A (en) | 1973-10-01 | 1977-03-22 | Bristol-Myers Company | Antiviral, substituted 1,3-dimethyl-1h-pyrazolo(3,4b)quinolines |
US4052393A (en) | 1975-11-03 | 1977-10-04 | E. R. Squibb & Sons, Inc. | 4-Substituted derivatives of pyrazolo [1,5-a]-quinoxaline-3-carboxylic acids and esters |
US4197403A (en) | 1977-01-07 | 1980-04-08 | Westwood Pharmaceuticals Inc. | 4-Aminosubstituted imidazo(1,2-A)quinoxalines |
US4191767A (en) | 1977-01-07 | 1980-03-04 | Westwood Pharmaceuticals, Inc. | Method for treating fungal infection in mammals with imidazo [1,2-a]quinoxalines |
US4722941A (en) | 1978-06-07 | 1988-02-02 | Kali-Chemie Pharma Gmbh | Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof |
US4411893A (en) | 1981-08-14 | 1983-10-25 | Minnesota Mining And Manufacturing Company | Topical medicament preparations |
DE3364438D1 (en) | 1982-10-18 | 1986-08-14 | Pfizer | Triazoloquinoxalines as antidepressants and antifatigue agents |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
CA1248450A (en) | 1984-04-05 | 1989-01-10 | Kazuo Kigasawa | Soft patch |
EP0187705A3 (en) | 1985-01-08 | 1988-05-11 | Norwich Eaton Pharmaceuticals, Inc. | Imidazo(4,5-f)quinolines useful as immunomodulating agents |
US4751087A (en) | 1985-04-19 | 1988-06-14 | Riker Laboratories, Inc. | Transdermal nitroglycerin delivery system |
US4908389A (en) | 1986-08-27 | 1990-03-13 | Warner-Lambert Company | Penetration enhancement system |
US4863970A (en) | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
US4746515A (en) | 1987-02-26 | 1988-05-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolaurate |
EP0375689B1 (en) | 1987-06-01 | 1992-08-12 | Warner-Lambert Company | A pharmaceutical composition adapted for transdermal delivery of an opoid drug. |
US5238944A (en) * | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
NZ232740A (en) | 1989-04-20 | 1992-06-25 | Riker Laboratories Inc | Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster |
ES2186034T3 (es) | 1991-03-01 | 2003-05-01 | Minnesota Mining & Mfg | Intermedios para la preparacion de 1h-imidazo(4,5-c)quinolin-4-aminas 1-sustituidas, 2-sustituidas. |
ATE195735T1 (de) | 1993-07-15 | 2000-09-15 | Minnesota Mining & Mfg | Imidazo (4,5-c)pyridin-4-amine |
KR100518903B1 (ko) | 1996-10-25 | 2005-10-06 | 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 | Th2 매개 질병 및 관련 질병의 치료용 면역 반응 조절 화합물 |
US5939090A (en) | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
EP0877089A1 (en) | 1997-05-07 | 1998-11-11 | Gist-Brocades B.V. | HMG-CoA reductase inhibitor preparation process |
UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
SI1512685T1 (sl) | 1997-12-11 | 2006-12-31 | Minnesota Mining & Mfg | Imidazonaftiridini in njihova uporaba v induciranju biosinteze citokina |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
IL144028A0 (en) | 1999-01-08 | 2002-04-21 | 3M Innovative Properties Co | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
US20020058674A1 (en) | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
RU2143900C1 (ru) * | 1999-03-31 | 2000-01-10 | Институт цитологии и генетики СО РАН | Способ получения изониазида пролонгированного действия |
DE19941509A1 (de) | 1999-08-31 | 2001-03-29 | Interconnectron Ges Fuer Ind S | Rundsteckverbinder zur Herstellung elektrischer Leitungsverbindungen |
US6464937B2 (en) * | 2000-11-01 | 2002-10-15 | Pml Microbiologicals, Inc. | Ultrapure sterilization of microbiological test media by electron beam irradiation |
US20030026794A1 (en) | 2001-07-31 | 2003-02-06 | Howard Fein | Selective enzyme treatment of skin conditions |
CN100473384C (zh) | 2001-11-29 | 2009-04-01 | 3M创新有限公司 | 包括免疫反应改性剂的药物制剂 |
US20060183767A1 (en) | 2003-01-06 | 2006-08-17 | Eugene Mandrea | Methods of stimulating immune response in certain individuals |
MXPA05009694A (es) | 2003-03-13 | 2005-10-20 | 3M Innovative Properties Co | Metodos para mejorar la calidad de la piel. |
AU2004268665A1 (en) | 2003-09-02 | 2005-03-10 | 3M Innovative Properties Company | Methods related to the treatment of mucosal associated conditions |
US20050175630A1 (en) | 2003-12-23 | 2005-08-11 | Eyal Raz | Immunogenic compositions and methods of use thereof |
EP1602365A1 (en) * | 2004-03-03 | 2005-12-07 | Switch Biotech Aktiengesellschaft | Pharmaceutical composition for topical use in form of xerogels or films and methods for production |
US20050201959A1 (en) | 2004-03-11 | 2005-09-15 | Vvii Newco 2003, Inc. | Methods and compositions for altering skin coloration |
WO2006029223A2 (en) | 2004-09-08 | 2006-03-16 | Children's Medical Center Corporation | Method for stimulating the immune response of newborns |
US8080560B2 (en) | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
US8436176B2 (en) | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
-
2007
- 2007-07-13 AU AU2007279376A patent/AU2007279376B2/en not_active Ceased
- 2007-07-13 US US12/309,778 patent/US8124096B2/en not_active Expired - Fee Related
- 2007-07-13 CA CA002659733A patent/CA2659733A1/en not_active Abandoned
- 2007-07-13 WO PCT/US2007/016001 patent/WO2008016475A2/en active Application Filing
- 2007-07-17 ME MEP-206/08A patent/MEP20608A/xx unknown
- 2007-07-17 IL IL184652A patent/IL184652A/en not_active IP Right Cessation
- 2007-07-19 PT PT07014182T patent/PT1891953E/pt unknown
- 2007-07-19 EP EP07014182A patent/EP1891953B1/en active Active
- 2007-07-19 SI SI200730851T patent/SI1891953T1/sl unknown
- 2007-07-19 PL PL07014182T patent/PL1891953T3/pl unknown
- 2007-07-19 ES ES07014182T patent/ES2375744T3/es active Active
- 2007-07-19 AT AT07014182T patent/ATE532511T1/de active
- 2007-07-19 RS RS20120043A patent/RS52120B/sr unknown
- 2007-07-19 DK DK07014182.5T patent/DK1891953T3/da active
- 2007-07-25 NO NO20073913A patent/NO338958B1/no not_active IP Right Cessation
- 2007-07-26 AR ARP070103329A patent/AR062121A1/es unknown
- 2007-07-27 RS RSP-2007/0318A patent/RS20070318A/sr unknown
- 2007-07-30 UA UAA200708769A patent/UA93496C2/uk unknown
- 2007-07-30 RU RU2007129104/15A patent/RU2474425C2/ru not_active IP Right Cessation
- 2007-07-30 UY UY30513A patent/UY30513A1/es not_active Application Discontinuation
- 2007-07-31 CL CL2007002228A patent/CL2007002228A1/es unknown
- 2007-07-31 PE PE2007000992A patent/PE20080523A1/es not_active Application Discontinuation
-
2009
- 2009-01-26 ZA ZA200900618A patent/ZA200900618B/xx unknown
-
2012
- 2012-01-23 CY CY20121100077T patent/CY1112264T1/el unknown
- 2012-02-07 HR HR20120128T patent/HRP20120128T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
ES2375744T3 (es) | 2012-03-05 |
CY1112264T1 (el) | 2015-12-09 |
NO20073913L (no) | 2008-02-01 |
SI1891953T1 (sl) | 2012-05-31 |
RU2007129104A (ru) | 2009-02-10 |
UY30513A1 (es) | 2008-02-29 |
ZA200900618B (en) | 2010-03-31 |
RS52120B (sr) | 2012-08-31 |
AU2007279376A1 (en) | 2008-02-07 |
PT1891953E (pt) | 2012-01-24 |
US8124096B2 (en) | 2012-02-28 |
MEP20608A (en) | 2010-06-10 |
IL184652A (en) | 2014-02-27 |
IL184652A0 (en) | 2008-01-20 |
ATE532511T1 (de) | 2011-11-15 |
UA93496C2 (uk) | 2011-02-25 |
WO2008016475A3 (en) | 2008-11-20 |
NO338958B1 (no) | 2016-11-07 |
RU2474425C2 (ru) | 2013-02-10 |
HRP20120128T1 (hr) | 2012-03-31 |
PE20080523A1 (es) | 2008-07-13 |
AR062121A1 (es) | 2008-10-15 |
DK1891953T3 (da) | 2012-02-27 |
PL1891953T3 (pl) | 2012-04-30 |
US20100096287A1 (en) | 2010-04-22 |
EP1891953A1 (en) | 2008-02-27 |
EP1891953B1 (en) | 2011-11-09 |
AU2007279376B2 (en) | 2012-09-06 |
WO2008016475A2 (en) | 2008-02-07 |
CA2659733A1 (en) | 2008-02-07 |
CL2007002228A1 (es) | 2008-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS20070318A (en) | Sterile formulations of modifier of immune response and processes | |
MX391854B (es) | Formulaciones farmaceuticas que contienen hidrato de propilenglicol de dapagliflozina | |
CL2007002095A1 (es) | Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composicion empacada; metodo para esterilizarla; util para cicatrizar tejido donde la dermis se ha desgarrado. | |
TW200517150A (en) | Mist sterilization system | |
PL1888127T3 (pl) | Sposób sterylizacji urządzenia medycznego posiadającego powłokę hydrofilową | |
ZA200809864B (en) | Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic | |
WO2005067986A8 (en) | Sterilization system and device | |
UA94928C2 (en) | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine | |
WO2007090661A3 (en) | Active substance combination comprising azolylcarbinol compounds | |
SG135189A1 (en) | High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products | |
UY25192A1 (es) | Formulación medicamentosa con liberación controlada de sustancia activa | |
NO20071485L (no) | Kjemiske substanser. | |
WO2004091591A3 (fr) | Composition nutritionnelle ou therapeutique contenant le compose oleurofeine ou l'un de ses derives | |
SG162614A1 (en) | Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors | |
GB2446341A (en) | Method and system for transdermal drug delivery | |
AR064152A1 (es) | Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion. | |
CY1111059T1 (el) | Φωτοσταθερη φαρμακευτικη συνθεση η οποια περιεχει βριβουδινη για την αγωγη της ερπητικης κερατιτιδας | |
IL195062A0 (en) | Process for the preparation of solid sterile active pharmaceutical ingredient | |
UA87291C2 (ru) | Пероральное пленкообразное лекарственное средство дезоксипеганина и способ его применения | |
EP1603595A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE | |
WO2008049915A3 (de) | Verfahren zum sterilisieren eines folienbehälters | |
EP1852119A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING A PHENOXAZINE COMPOUND AS AN ACTIVE SUBSTANCE | |
MXPA05005460A (es) | Contraste de ultrasonido que usa xantenos halogenados. | |
PT1889629E (pt) | Formulação estável compreendendo uma associação de um fármaco sensível à humidade e de um segundo fármaco e processo para o seu fabrico | |
MY140242A (en) | BICYCLIC 6-ALKYLIDENE-PENEMS AS ß-LACTAMASES INHIBITORS |